LY-3177833 (LY3177833)

Background Information:

LY-3177833 (optically pure) is a clinical stage, orally available,
potent and selective inhibitor of CDC7 (Cell Division Cycle 7-related
Protein Kinase), inhibiting CDC7/DBF4 I and pMCM2 (S53) with IC50 values
of 3.3 nM and 290 nM, respectively. The inhibition profoundly impacts
chromosome dynamics. Broad antitumor activity was associated with robust
dose/exposure-dependent in vivo target inhibition in mouse xenograft
models. In addition, the preclinical profile of the compound was
different from nonselective CDC7 inhibitors and cytotoxic agents, which
supports its clinical development with a continuous dosing regimen (ref.
1).

Reference:

1. Buyer Beware: Be careful the poor optical purity (partially
racemized with significant wrong isomer content) LY-3177833 on market,
without Chiral HPLC analysis.

APIM050190: LY-3177833 (LY3177833)

CAS No.: 1627696-51-8.
Molecular Formula: C16H12FN5O.
Molecular Weight: 309.3 (or refer to Certificate, batch-specific).
Purity: >99.5% chem and Optical Purity.
QC: HPLC-MS, 1H-NMR, Chiral HPLC, and Quantitative Elemental Analysis Report.
Solubility: Refer to Certificate.
Storage: Refer to Certificate.